TargetBeta
IL31RA
interleukin 31 receptor A · also CRL3, GLM-R, CRL, Glmr · Fibronectin type III domain containing
2 programs in company-led studies act on IL31RA, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| nemolizumabrule | Galderma Group | phase 4 | 236 running | – | ChEMBL |
| ABBV-313 | AbbVie | phase 1 | 11 running | IL13 | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Dermatitis, Atopic, 1 program
- Prurigo, 1 program
- Pruritus, 1 program
- Renal Insufficiency, Chronic, 1 program
- Scleroderma, Systemic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026nemolizumab · Galderma Group · phase 4 · NCT07074977
- Feb 2028ABBV-313 · AbbVie · phase 1 · NCT07673120
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.